eli lilly glp 1 agonist Lilly's Easy-to Use Once-Weekly GLP-1 Trulicity Approved in Europe Administration Anounces Landmark GLP-1 Pricing

Still, these perceptions are not static and may shift as confidence in oral approaches grows

This alarming trend has led to a heightened demand for effective pharmacological interventions, particularly GLP-1 receptor agonists, which have demonstrated efficacy in weight loss and glycemic control

Dulaglutide is less likely to cause injection site reactions (0.5%) than most other GLP analogs (although Ozempic is lower at 0.2%)

October 2025: More research shows that Zepbound and other GLP-1s raise the chances of someone experiencing blindness and other vision complications

Although the reasons for the variation are still unclear, this might be due to several differences in the individual study design and patient characteristics rather than drug effect [21]

DOI: 10.1016/0306-4603(82)90024-7